Related Experiment Video

Updated: Oct 15, 2025

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.9K

Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful

Carlo Avolio1,2, Diego Centonze3,4

  • 1Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. carlo.avolio@unifg.it.

Neurology and Therapy
|October 31, 2021
PubMed

Insights

Current multiple sclerosis (MS) drug trials lack personalized patient criteria, hindering research progress. Standardized inclusion and outcome measures are needed for effective MS research strategies and drug development.

Area of Science:

  • Neurology
  • Clinical Trials
  • Pharmacology

Background:

  • Major randomized trials for multiple sclerosis (MS) have varying inclusion criteria and outcome measures.
  • This heterogeneity complicates the direct comparison of trial results and the interpretation of new drug efficacy.

Purpose of the Study:

  • To critically evaluate the inclusion criteria and outcome measures used in key multiple sclerosis randomized trials.
  • To foster discussion on enhancing research strategies for more impactful advancements in multiple sclerosis treatment.

Main Methods:

  • Qualitative comparison of patient characteristics across major multiple sclerosis clinical trials.
  • Analysis of common and divergent inclusion and outcome measure methodologies.

Main Results:

  • Significant variability exists in patient selection and outcome assessment in multiple sclerosis trials.
  • Current research strategies without personalized criteria limit meaningful knowledge advancement in drug discovery.

Conclusions:

  • There is a pressing need to refine and standardize inclusion criteria and outcome measures in multiple sclerosis research.
  • Adopting personalized criteria in clinical trials is essential for accelerating progress in understanding and treating multiple sclerosis.
Keywords:
CladribineDimethyl fumarateDiroximel fumarateFingolimodOcrelizumabOfatumumabOzanimodPonesimodTeriflunomide

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.2K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.7K

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
14
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.8K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.7K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
16
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
21
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
15